SCHEMBL72310

SCHEMBL72310

[CH2]CCC(=O)c1cccs1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.77
LMNA P02545 3/20 0.77
KMT2A Q03164 3/20 0.77
MEN1 O00255 2/20 0.77
NPC1 O15118 2/20 0.77
RAB9A P51151 2/20 0.77
POLB P06746 1/20 0.77
HPGD P15428 5/20 0.61
L3MBTL1 Q9Y468 3/20 0.61
PKM P14618 1/20 0.61
TSHR P16473 1/20 0.61
MAPK1 P28482 1/20 0.61
HTT P42858 1/20 0.61
HSD17B10 Q99714 1/20 0.61
GSK3B P49841 1/20 0.60
CTNNB1 P35222 5/20 0.56
WNT3A P56704 4/20 0.56
HDAC1 Q13547 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
ERCC5 P28715 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2216212 0.87 ALDH1A1 (1.00) ALDH1A1LMNAKMT2AMEN1NPC1
SCHEMBL27593116 0.87 HPGD (0.70) ALDH1A1LMNAKMT2AMEN1NPC1
SCHEMBL352209 0.83
SCHEMBL22721189 0.83 ALDH1A1 (0.83) ALDH1A1LMNAKMT2AMEN1NPC1
SCHEMBL6423116 0.82 ALDH1A1 (0.80) ALDH1A1LMNAKMT2AMEN1NPC1
SCHEMBL8521100 0.82 ALDH1A1 (0.80) ALDH1A1LMNAKMT2AMEN1NPC1
SCHEMBL6197414 0.82 ALDH1A1 (0.80) ALDH1A1LMNAKMT2AMEN1NPC1
SCHEMBL3224084 0.82 ALDH1A1 (0.80) ALDH1A1LMNAKMT2AMEN1NPC1
SCHEMBL10352206 0.80 ALDH1A1 (0.77) ALDH1A1LMNAKMT2AMEN1NPC1
SCHEMBL759462 0.80 ALDH1A1 (0.84) ALDH1A1LMNAKMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879874-B2 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis ALMIRALL, S.A. (ES) 2011-02-01 US claimed
US-20100234332-A1 NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME PRAT QUINONES MARIA 2010-09-16 US claimed
US-20070129398-A1 Novel quinuclidine derivatives and medicinal compositions containing the same ALMIRALL, S.A. (ES) 2007-06-07 US claimed
US-20070129420-A1 New pyrrolidinium derivatives ALMIRALL PRODESFARMA SA 2007-06-07 US claimed
US-20070105897-A1 Novel quinuclidine derivatives and medicinal compositions containing the same ALMIRALL, S.A. (ES) 2007-05-10 US claimed
EP-1353919-B1 NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME ALMIRALL PRODESFARMA AG (CH) 2006-07-26 EP claimed
US-20050282875-A1 Pyrrolidinium derivatives LABORATORIOS ALMIRALL S.A. (ES) 2005-12-22 US claimed
EP-1497284-A2 PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS Almirall Prodesfarma AG (CH) 2005-01-19 EP claimed
US-20040072863-A1 Novel quinuclidine derivatives and medicinal compositions containing the same ALMIRALL, S.A. (ES) 2004-04-15 US claimed
WO-2003087094-A2 PYRROLIDINIUM DERIVATIVES AS ANTAGONISTS OF M3 MUSCARINIC RECEPTORS ALMIRALL PRODESFARMA AG (CH) 2003-10-23 WO claimed
EP-1353919-A2 NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Almirall Prodesfarma AG (CH) 2003-10-22 EP claimed
WO-2002053564-A2 QUINUCLIDINE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2002-07-11 WO claimed
CN-1090581-A The preparation method of the novel derivative of erythromycin and they and as the application of medicine ROUSSEL UCLAF (FR) 1994-08-10 CN claimed
US-10588895-B2 Quinuclidine derivatives and medicinal compositions containing the same ALMIRALL, S.A. (ES) 2020-03-17 US disclosed
US-20190183867-A1 NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME ALMIRALL SA (ES) 2019-06-20 US disclosed
US-10034867-B2 Quinuclidine derivatives and medicinal compositions containing the same ALMIRALL, S.A. (ES) 2018-07-31 US disclosed
EP-1200431-A2 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR LIGANDS Almirall Prodesfarma, S.A. (ES) 2002-05-02 EP disclosed
WO-2001004118-A2 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR LIGANDS ALMIRALL PRODESFARMA S.A. (ES) 2001-01-18 WO disclosed
CN-1040876-C New derivatives of erythromycin, their preparation process, their use as medicaments ROUSSEL UCLAF (FR) 1998-11-25 CN disclosed
CN-1090581-A The preparation method of the novel derivative of erythromycin and they and as the application of medicine ROUSSEL UCLAF (FR) 1994-08-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10034867-B2 Quinuclidine derivatives and medicinal compositions containing the same H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 ALDH1A1 1663/4885LMNA 2813/4885KMT2A 1698/4885
US-20050282875-A1 Pyrrolidinium derivatives CHRM3, CHRM2, CHRM1 ALDH1A1 975/4885LMNA 4307/4885KMT2A 4205/4885
US-20070129420-A1 New pyrrolidinium derivatives CHRM3, CHRM2, CHRM1 ALDH1A1 1369/4885LMNA 4257/4885KMT2A 4240/4885
US-20070129398-A1 Novel quinuclidine derivatives and medicinal compositions containing the same NR0B1, NR2C2, NR1I3 ALDH1A1 1964/4885LMNA 3397/4885KMT2A 2561/4885
US-20190183867-A1 NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME CHRM3, CHRNB1, ARRB1 ALDH1A1 1419/4885LMNA 4706/4885KMT2A 3203/4885
US-20100234332-A1 NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME NR0B1, NR4A1, NR0B2 ALDH1A1 1880/4885LMNA 3455/4885KMT2A 2628/4885
US-20040072863-A1 Novel quinuclidine derivatives and medicinal compositions containing the same CYP11B1, CYP3A7, CBR1 ALDH1A1 1368/4885LMNA 1971/4885KMT2A 2107/4885
US-20070105897-A1 Novel quinuclidine derivatives and medicinal compositions containing the same NR0B1, NR4A1, NR0B2 ALDH1A1 1864/4885LMNA 3282/4885KMT2A 3072/4885
US-10588895-B2 Quinuclidine derivatives and medicinal compositions containing the same CHRM3, QDPR, CHRM2 ALDH1A1 1142/4885LMNA 4535/4885KMT2A 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.